Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single Dose escalation Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Immunogenicity, and Initial efficacy of SGC001 in Patients Scheduled to undergo Percutaneous Coronary Intervention for Anterior ST-segment Elevation Myocardial Infarction

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Dose escalation Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Immunogenicity, and Initial efficacy of SGC001 in Patients Scheduled to undergo Percutaneous Coronary Intervention for Anterior ST-segment Elevation Myocardial Infarction

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dukiprubart (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Apr 2025 New source identified and integrated (Chinese Clinical Trial Register;ChiCTR2500096142).
    • 08 Apr 2025 New trial record
    • 19 Mar 2025 According to Sungen Biomedical media release, the company has received approval to this study from China NMPA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top